Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-05-25Actual
Enrollment · participants15Actual
Source updated2023-09-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.